;PMID: 1530660
;source_file_653.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..231] = [t:49..231]
;2)section:[e:235..257] = [t:235..257]
;3)section:[e:261..313] = [t:261..313]
;4)sentence:[e:317..561] = [t:317..561]
;5)sentence:[e:562..786] = [t:562..786]
;6)sentence:[e:787..1011] = [t:787..1011]
;7)sentence:[e:1012..1230] = [t:1012..1230]
;8)sentence:[e:1231..1443] = [t:1231..1443]
;9)sentence:[e:1444..1597] = [t:1444..1597]
;10)sentence:[e:1598..1897] = [t:1598..1897]
;11)sentence:[e:1899..2276] = [t:1899..2276]
;12)sentence:[e:2277..2583] = [t:2277..2583]
;13)section:[e:2587..2631] = [t:2587..2631]

;section 0 Span:0..43
;Biochem Pharmacol. 1992 Sep 1;44(5):913-20.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (CD:[19..23] 1992) (NNPS:[24..27] Sep) (CD:[28..33] 1;44-LRB-)
        (CD:[33..34] 5) (-RRB-:[34..35] -RRB-) (CD:[35..39] :913)
        (IN:[39..40] -) (CD:[40..42] 20) (.:[42..43] .)))

;sentence 1 Span:49..231
;Activation of 6-aminochrysene to genotoxic products by different forms of rat
; liver cytochrome P450 in an O-acetyltransferase-overexpressing Salmonella 
;typhimurium strain (NM2009).
;[63..78]:substance:"6-aminochrysene"
;[92..100]:substance:"products"
;[134..149]:cyp450:"cytochrome P450"
;[156..175]:substance:"O-acetyltransferase"
(SENT
  (NP-HLN
    (NP (NN:[49..59] Activation))
    (PP (IN:[60..62] of)
      (NP (NN:[63..78] 6-aminochrysene)))
    (PP (TO:[79..81] to)
      (NP (JJ:[82..91] genotoxic) (NNS:[92..100] products)))
    (PP (IN:[101..103] by)
      (NP
        (NP (JJ:[104..113] different) (NNS:[114..119] forms))
        (PP (IN:[120..122] of)
          (NP (NN:[123..126] rat) (NN:[128..133] liver)
             (NN:[134..144] cytochrome) (NN:[145..149] P450)))))
    (PP-LOC (IN:[150..152] in)
      (NP
        (NP (DT:[153..155] an)
          (ADJP (NN:[156..175] O-acetyltransferase) (HYPH:[175..176] -)
                (VBG:[176..190] overexpressing))
          (NML (NNP:[191..201] Salmonella) (NNP:[203..214] typhimurium))
          (NN:[215..221] strain))
        (NP (-LRB-:[222..223] -LRB-) (NN:[223..229] NM2009)
            (-RRB-:[229..230] -RRB-))))
    (.:[230..231] .)))

;section 2 Span:235..257
;Yamazaki H, Shimada T.
(SEC
  (FRAG (NNP:[235..243] Yamazaki) (NNP:[244..245] H) (,:[245..246] ,)
        (NNP:[247..254] Shimada) (NNP:[255..257] T.)))

;section 3 Span:261..313
;Osaka Prefectural Institute of Public Health, Japan.
(SEC
  (FRAG (NNP:[261..266] Osaka) (NNP:[267..278] Prefectural)
        (NNP:[279..288] Institute) (IN:[289..291] of) (NNP:[292..298] Public)
        (NNP:[299..305] Health) (,:[305..306] ,) (NNP:[307..312] Japan)
        (.:[312..313] .)))

;sentence 4 Span:317..561
;Metabolic activation of a potent mutagen, 6-aminochrysene, to genotoxic
;products  in a newly developed tester strain, Salmonella typhimurium NM2009,
;was studied  in a rat liver microsomal monooxygenase system containing
;cytochrome P450  (P450).
;[350..357]:substance:"mutagen"
;[359..374]:substance:"6-aminochrysene"
;[389..397]:substance:"products"
;[505..518]:substance:"monooxygenase"
;[537..552]:cyp450:"cytochrome P450"
;[555..559]:cyp450:"P450"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[317..326] Metabolic) (NN:[327..337] activation))
      (PP (IN:[338..340] of)
        (NP
          (NP (DT:[341..342] a) (JJ:[343..349] potent) (NN:[350..357] mutagen))
          (,:[357..358] ,)
          (NP (NN:[359..374] 6-aminochrysene))))
      (,:[374..375] ,)
      (PP (TO:[376..378] to)
        (NP (JJ:[379..388] genotoxic) (NNS:[389..397] products)))
      (PP-LOC (IN:[399..401] in)
        (NP
          (NP (DT:[402..403] a)
            (ADJP (RB:[404..409] newly) (VBN:[410..419] developed))
            (NN:[420..426] tester) (NN:[427..433] strain))
          (,:[433..434] ,)
          (NP (NNP:[435..445] Salmonella) (NNP:[446..457] typhimurium)
              (NN:[458..464] NM2009)))))
    (VP (,:[464..465] ,) (VBD:[466..469] was)
      (VP (VBN:[470..477] studied)
        (NP-1 (-NONE-:[477..477] *))
        (PP-LOC (IN:[479..481] in)
          (NP
            (NP (DT:[482..483] a) (NN:[484..487] rat) (NN:[488..493] liver)
                (JJ:[494..504] microsomal) (NN:[505..518] monooxygenase)
                (NN:[519..525] system))
            (VP (VBG:[526..536] containing)
              (NP
                (NP (NN:[537..547] cytochrome) (NN:[548..552] P450))
                (NP (-LRB-:[554..555] -LRB-) (NN:[555..559] P450)
                    (-RRB-:[559..560] -RRB-))))))))
    (.:[560..561] .)))

;sentence 5 Span:562..786
;Since the tester strain was constructed by introducing an 
;O-acetyltransferase gene into the original strain S. typhimurium
;TA1535/pSK1002,  it is highly sensitive toward the reactive metabolites of
;carcinogenic  arylamines.
;[746..757]:substance:"metabolites"
;[775..785]:substance:"arylamines"
(SENT
  (S
    (SBAR-ADV (IN:[562..567] Since)
      (S
        (NP-SBJ-1 (DT:[568..571] the) (NN:[572..578] tester)
                  (NN:[579..585] strain))
        (VP (VBD:[586..589] was)
          (VP (VBN:[590..601] constructed)
            (NP-1 (-NONE-:[601..601] *))
            (PP (IN:[602..604] by)
              (S-NOM
                (NP-SBJ (-NONE-:[604..604] *))
                (VP (VBG:[605..616] introducing)
                  (NP (DT:[617..619] an) (NN:[621..640] O-acetyltransferase)
                      (NN:[641..645] gene))
                  (PP-CLR (IN:[646..650] into)
                    (NP
                      (NP (DT:[651..654] the) (JJ:[655..663] original)
                          (NN:[664..670] strain))
                      (NP (NNP:[671..673] S.) (NNP:[674..685] typhimurium)
                          (NN:[686..692] TA1535) (SYM:[692..693] /)
                          (NN:[693..700] pSK1002)))))))))))
    (,:[700..701] ,)
    (NP-SBJ (PRP:[703..705] it))
    (VP (VBZ:[706..708] is)
      (ADJP-PRD (RB:[709..715] highly) (JJ:[716..725] sensitive)
        (PP (IN:[726..732] toward)
          (NP
            (NP (DT:[733..736] the) (JJ:[737..745] reactive)
                (NNS:[746..757] metabolites))
            (PP (IN:[758..760] of)
              (NP (JJ:[761..773] carcinogenic) (NNS:[775..785] arylamines)))))))
    (.:[785..786] .)))

;sentence 6 Span:787..1011
;DNA-damaging activities of 6-aminochrysene were detected at very low 
;concentrations of substrate (between 0.01 and 0.2 microM) and liver
;microsomes  (from 0.2 to 2 micrograms protein/mL) in the S. typhimurium
;NM2009 strain.
;[787..790]:substance:"DNA"
;[814..829]:substance:"6-aminochrysene"
;[875..884]:substance:"substrate"
;[894..898]:quantitative-value:"0.01"
;[903..906]:quantitative-value:"0.2"
;[907..913]:quantitative-units:"microM"
;[943..946]:quantitative-value:"0.2"
;[950..951]:quantitative-value:"2"
;[952..973]:quantitative-units:"micrograms protein/mL"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (ADJP (NN:[787..790] DNA) (HYPH:[790..791] -) (VBG:[791..799] damaging))
        (NNS:[800..810] activities))
      (PP (IN:[811..813] of)
        (NP (NN:[814..829] 6-aminochrysene))))
    (VP (VBD:[830..834] were)
      (VP (VBN:[835..843] detected)
        (NP-1 (-NONE-:[843..843] *))
        (PP (IN:[844..846] at)
          (NP
            (NP
              (ADJP (RB:[847..851] very) (JJ:[852..855] low))
              (NNS:[857..871] concentrations))
            (PP (IN:[872..874] of)
              (NP
                (NP (NN:[875..884] substrate)
                  (PP (-LRB-:[885..886] -LRB-)
                    (PP (IN:[886..893] between)
                      (NP
                        (NP (CD:[894..898] 0.01)
                          (NML-2 (-NONE-:[898..898] *P*)))
                        (CC:[899..902] and)
                        (NP (CD:[903..906] 0.2)
                          (NML-2 (NN:[907..913] microM)))))
                    (-RRB-:[913..914] -RRB-)))
                (CC:[915..918] and)
                (NP (NN:[919..924] liver) (NNS:[925..935] microsomes)
                  (PRN (-LRB-:[937..938] -LRB-)
                    (NP
                      (NP
                        (NML
                          (QP (IN:[938..942] from) (CD:[943..946] 0.2)
                              (TO:[947..949] to) (CD:[950..951] 2))
                          (NNS:[952..962] micrograms))
                        (NN:[963..970] protein))
                      (PP-5 (SYM:[970..971] /)
                        (NP (NN:[971..973] mL))))
                    (NN:[973..974] -RRB-)))))))
        (PP-LOC (IN:[975..977] in)
          (NP (DT:[978..981] the)
            (NML (NNP:[982..984] S.) (NNP:[985..996] typhimurium))
            (NN:[997..1003] NM2009) (NN:[1004..1010] strain)))))
    (.:[1010..1011] .)))

;sentence 7 Span:1012..1230
;Thus,  the potency of genotoxic activities induced by 6-aminochrysene was
;about 10- to  20-times greater than those induced by the well-known mutagens
;2-aminoanthracene  and 2-amino-3,5-dimethylimidazo[4,5-f]quinoline.
;[1066..1081]:substance:"6-aminochrysene"
;[1154..1162]:substance:"mutagens"
;[1163..1180]:substance:"2-aminoanthracene"
;[1186..1229]:substance:"2-amino-3,5-dimethylimidazo[4,5-f]quinoline"
(SENT
  (S
    (ADVP (RB:[1012..1016] Thus))
    (,:[1016..1017] ,)
    (NP-SBJ
      (NP
        (NP (DT:[1019..1022] the) (NN:[1023..1030] potency))
        (PP (IN:[1031..1033] of)
          (NP (JJ:[1034..1043] genotoxic) (NNS:[1044..1054] activities))))
      (VP (VBN:[1055..1062] induced)
        (NP (-NONE-:[1062..1062] *))
        (PP (IN:[1063..1065] by)
          (NP-LGS (NN:[1066..1081] 6-aminochrysene)))))
    (VP (VBD:[1082..1085] was)
      (ADJP-PRD
        (ADJP
          (NML
            (QP (IN:[1086..1091] about) (CD:[1092..1094] 10)
                (HYPH:[1094..1095] -) (TO:[1096..1098] to) (CD:[1100..1102] 20)
                (HYPH:[1102..1103] -) (NNS:[1103..1108] times)))
          (JJR:[1109..1116] greater))
        (PP (IN:[1117..1121] than)
          (NP
            (NP (DT:[1122..1127] those))
            (VP (VBN:[1128..1135] induced)
              (NP (-NONE-:[1135..1135] *))
              (PP (IN:[1136..1138] by)
                (NP-LGS
                  (NP (DT:[1139..1142] the)
                    (ADJP (RB:[1143..1147] well) (HYPH:[1147..1148] -)
                          (VBN:[1148..1153] known))
                    (NNS:[1154..1162] mutagens))
                  (NP (NN:[1163..1180] 2-aminoanthracene) (CC:[1182..1185] and)
                      (NN:[1186..1229] 2-amino-3,5-dimethylimidazo-LSB-4,5-f-RSB-quinoline)))))))))
    (.:[1229..1230] .)))

;sentence 8 Span:1231..1443
;Liver microsomes isolated from  rats treated with phenobarbital (PB) and a
;polychlorinated biphenyl mixture,  Kanechlor 500, catalyzed very efficiently
;the activation of 6-aminochrysene to  genotoxic metabolites.
;[1281..1294]:substance:"phenobarbital"
;[1296..1298]:substance:"PB"
;[1306..1338]:substance:"polychlorinated biphenyl mixture"
;[1341..1354]:substance:"Kanechlor 500"
;[1401..1416]:substance:"6-aminochrysene"
;[1431..1442]:substance:"metabolites"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1231..1236] Liver) (NNS:[1237..1247] microsomes))
      (VP (VBN:[1248..1256] isolated)
        (NP (-NONE-:[1256..1256] *))
        (PP (IN:[1257..1261] from)
          (NP
            (NP (NNS:[1263..1267] rats))
            (VP (VBN:[1268..1275] treated)
              (NP (-NONE-:[1275..1275] *))
              (PP-MNR (IN:[1276..1280] with)
                (NP
                  (NP
                    (NP (NN:[1281..1294] phenobarbital))
                    (NP (-LRB-:[1295..1296] -LRB-) (NN:[1296..1298] PB)
                        (-RRB-:[1298..1299] -RRB-)))
                  (CC:[1300..1303] and)
                  (NP
                    (NP (DT:[1304..1305] a)
                       (VBN:[1306..1321] polychlorinated)
                       (NN:[1322..1330] biphenyl) (NN:[1331..1338] mixture))
                    (,:[1338..1339] ,)
                    (NP (NN:[1341..1350] Kanechlor) (CD:[1351..1354] 500))))))))))
    (,:[1354..1355] ,)
    (VP (VBD:[1356..1365] catalyzed)
      (ADVP (RB:[1366..1370] very) (RB:[1371..1382] efficiently))
      (NP
        (NP (CC:[1383..1386] the) (NN:[1387..1397] activation))
        (PP (IN:[1398..1400] of)
          (NP (NN:[1401..1416] 6-aminochrysene)))
        (PP (TO:[1417..1419] to)
          (NP (JJ:[1421..1430] genotoxic) (NNS:[1431..1442] metabolites)))))
    (.:[1442..1443] .)))

;sentence 9 Span:1444..1597
;Treatment of rats with beta-naphthoflavone (BNF) and with  dexamethasone also
;caused moderate induction of the microsomal activation of  6-aminochrysene.
;[1467..1486]:substance:"beta-naphthoflavone"
;[1488..1491]:substance:"BNF"
;[1503..1516]:substance:"dexamethasone"
;[1581..1596]:substance:"6-aminochrysene"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1444..1453] Treatment))
      (PP (IN:[1454..1456] of)
        (NP (NNS:[1457..1461] rats)))
      (PP
        (PP (IN:[1462..1466] with)
          (NP
            (NP (SYM:[1467..1471] beta) (HYPH:[1471..1472] -)
                (NN:[1472..1486] naphthoflavone))
            (NP (-LRB-:[1487..1488] -LRB-) (NN:[1488..1491] BNF)
                (-RRB-:[1491..1492] -RRB-))))
        (CC:[1493..1496] and)
        (PP (IN:[1497..1501] with)
          (NP (NN:[1503..1516] dexamethasone)))))
    (ADVP (RB:[1517..1521] also))
    (VP (VBD:[1522..1528] caused)
      (NP
        (NP (JJ:[1529..1537] moderate) (NN:[1538..1547] induction))
        (PP (IN:[1548..1550] of)
          (NP
            (NP (DT:[1551..1554] the) (JJ:[1555..1565] microsomal)
                (NN:[1566..1576] activation))
            (PP (IN:[1577..1579] of)
              (NP (NN:[1581..1596] 6-aminochrysene)))))))
    (.:[1596..1597] .)))

;sentence 10 Span:1598..1897
;Studies employing immunoinhibition of microsomal catalytic  activities and
;reconstitution with purified P450 enzymes suggested that the most  important
;enzymes involved in the activation of 6-aminochrysene were P450 2B1  and 2B2;
;other enzymes including P450 1A1 and 1A2 participated to some extent.
;[1702..1714]:cyp450:"P450 enzymes"
;[1750..1757]:cyp450:"enzymes"
;[1788..1803]:substance:"6-aminochrysene"
;[1809..1817]:cyp450:"P450 2B1"
;[1809..1813]...[1823..1826]:cyp450:"P450"..."2B2"
;[1834..1841]:cyp450:"enzymes"
;[1852..1860]:cyp450:"P450 1A1"
;[1852..1856]...[1865..1868]:cyp450:"P450"..."1A2"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1598..1605] Studies))
      (VP (VBG:[1606..1615] employing)
        (NP
          (NP
            (NP (NN:[1616..1632] immunoinhibition))
            (PP (IN:[1633..1635] of)
              (NP (JJ:[1636..1646] microsomal) (JJ:[1647..1656] catalytic)
                  (NNS:[1658..1668] activities))))
          (CC:[1669..1672] and)
          (NP
            (NP (NN:[1673..1687] reconstitution))
            (PP (IN:[1688..1692] with)
              (NP (VBN:[1693..1701] purified)
                 (NN:[1702..1706] P450) (NNS:[1707..1714] enzymes)))))))
    (VP (VBD:[1715..1724] suggested)
      (SBAR (IN:[1725..1729] that)
        (S
          (NP-SBJ
            (NP (DT:[1730..1733] the)
              (ADJP (RBS:[1734..1738] most) (JJ:[1740..1749] important))
              (NNS:[1750..1757] enzymes))
            (VP (VBN:[1758..1766] involved)
              (NP (-NONE-:[1766..1766] *))
              (PP-CLR (IN:[1767..1769] in)
                (NP
                  (NP (DT:[1770..1773] the) (NN:[1774..1784] activation))
                  (PP (IN:[1785..1787] of)
                    (NP (NN:[1788..1803] 6-aminochrysene)))))))
          (VP (VBD:[1804..1808] were)
            (NP-PRD
              (NP
                (NML-1 (NN:[1809..1813] P450))
                (NN:[1814..1817] 2B1))
              (CC:[1819..1822] and)
              (NP
                (NML-1 (-NONE-:[1822..1822] *P*))
                (NN:[1823..1826] 2B2)))))))
    (::[1826..1827] ;)
    (S
      (NP-SBJ
        (NP (JJ:[1828..1833] other) (NNS:[1834..1841] enzymes))
        (PP (VBG:[1842..1851] including)
          (NP
            (NP
              (NML-2 (NN:[1852..1856] P450))
              (NN:[1857..1860] 1A1))
            (CC:[1861..1864] and)
            (NP
              (NML-2 (-NONE-:[1864..1864] *P*))
              (NN:[1865..1868] 1A2)))))
      (VP (VBD:[1869..1881] participated)
        (PP (TO:[1882..1884] to)
          (NP (DT:[1885..1889] some) (NN:[1890..1896] extent)))))
    (.:[1896..1897] .)))

;sentence 11 Span:1899..2276
;We also found that the microsomal activation of 6-aminochrysene was catalyzed
; more effectively in an acetyltransferase-overexpressing strain (NM2009) than
;in  the original TA1535/pSK1002 strain and that these activities could be
;inhibited  by an acetyltransferase inhibitor, pentachlorophenol, in liver
;microsomes from  PB-treated rats, but not in those from BNF-treated rats.
;[1947..1962]:substance:"6-aminochrysene"
;[2001..2018]:substance:"acetyltransferase"
;[2146..2163]:substance:"acetyltransferase"
;[2164..2173]:substance:"inhibitor"
;[2175..2192]:substance:"pentachlorophenol"
;[2220..2222]:substance:"PB"
;[2259..2262]:substance:"BNF"
(SENT
  (S
    (NP-SBJ (PRP:[1899..1901] We))
    (ADVP (RB:[1902..1906] also))
    (VP (VBD:[1907..1912] found)
      (SBAR
        (SBAR (IN:[1913..1917] that)
          (S
            (NP-SBJ-4
              (NP (DT:[1918..1921] the) (JJ:[1922..1932] microsomal)
                  (NN:[1933..1943] activation))
              (PP (IN:[1944..1946] of)
                (NP (NN:[1947..1962] 6-aminochrysene))))
            (VP (VBD:[1963..1966] was)
              (VP (VBN:[1967..1976] catalyzed)
                (NP-4 (-NONE-:[1976..1976] *))
                (ADVP
                  (ADVP (RBR:[1978..1982] more) (RB:[1983..1994] effectively))
                  (PP-5 (-NONE-:[1994..1994] *ICH*)))
                (PP-LOC (IN:[1995..1997] in)
                  (NP
                    (NP (DT:[1998..2000] an)
                      (ADJP (NN:[2001..2018] acetyltransferase)
                            (HYPH:[2018..2019] -)
                            (VBG:[2019..2033] overexpressing))
                      (NN:[2034..2040] strain))
                    (NP (-LRB-:[2041..2042] -LRB-) (NN:[2042..2048] NM2009)
                        (-RRB-:[2048..2049] -RRB-))))
                (PP-5 (IN:[2050..2054] than)
                  (PP (IN:[2055..2057] in)
                    (NP-LOC (DT:[2059..2062] the) (JJ:[2063..2071] original)
                      (NML (NN:[2072..2078] TA1535) (SYM:[2078..2079] /)
                           (NN:[2079..2086] pSK1002))
                      (NN:[2087..2093] strain))))))))
        (CC:[2094..2097] and)
        (SBAR (IN:[2098..2102] that)
          (S
            (NP-SBJ-3 (DT:[2103..2108] these) (NNS:[2109..2119] activities))
            (VP (MD:[2120..2125] could)
              (VP (VB:[2126..2128] be)
                (VP
                  (VP (VBN:[2129..2138] inhibited)
                    (NP-3 (-NONE-:[2138..2138] *))
                    (PP (IN:[2140..2142] by)
                      (NP-LGS
                        (NP (DT:[2143..2145] an)
                            (NN:[2146..2163] acetyltransferase)
                            (NN:[2164..2173] inhibitor))
                        (,:[2173..2174] ,)
                        (NP (NN:[2175..2192] pentachlorophenol))))
                    (,:[2192..2193] ,)
                    (PP-LOC=1 (IN:[2194..2196] in)
                      (NP
                        (NP (NN:[2197..2202] liver)
                            (NNS:[2203..2213] microsomes))
                        (PP (IN:[2214..2218] from)
                          (NP
                            (ADJP (NN:[2220..2222] PB) (HYPH:[2222..2223] -)
                                  (VBN:[2223..2230] treated))
                            (NNS:[2231..2235] rats))))))
                  (,:[2235..2236] ,) (CC:[2237..2240] but)
                  (VP (RB:[2241..2244] not)
                    (PP-LOC=1 (IN:[2245..2247] in)
                      (NP
                        (NP (DT:[2248..2253] those))
                        (PP (IN:[2254..2258] from)
                          (NP
                            (ADJP (NN:[2259..2262] BNF) (HYPH:[2262..2263] -)
                                  (VBN:[2263..2270] treated))
                            (NNS:[2271..2275] rats)))))))))))))
    (.:[2275..2276] .)))

;sentence 12 Span:2277..2583
;These results suggest  that the P450/acetyltransferase system is one of the
;most important catalysts  for the activation of 6-aminochrysene in liver
;microsomes of PB-treated rats,  and that activation by BNF-induced P450
;enzymes occurs by different mechanisms,  probably through the ring oxidation
;pathway.
;[2309..2313]:cyp450:"P450"
;[2314..2331]:substance:"acetyltransferase"
;[2368..2377]:substance:"catalysts"
;[2401..2416]:substance:"6-aminochrysene"
;[2440..2442]:substance:"PB"
;[2481..2484]:substance:"BNF"
;[2493..2505]:cyp450:"P450 enzymes"
(SENT
  (S
    (NP-SBJ (DT:[2277..2282] These) (NNS:[2283..2290] results))
    (VP (VBP:[2291..2298] suggest)
      (SBAR
        (SBAR (IN:[2300..2304] that)
          (S
            (NP-SBJ (DT:[2305..2308] the)
              (NML (NN:[2309..2313] P450) (SYM:[2313..2314] /)
                   (NN:[2314..2331] acetyltransferase))
              (NN:[2332..2338] system))
            (VP (VBZ:[2339..2341] is)
              (NP-PRD
                (NP (CD:[2342..2345] one))
                (PP (IN:[2346..2348] of)
                  (NP
                    (NP (DT:[2349..2352] the)
                      (ADJP (RBS:[2353..2357] most) (JJ:[2358..2367] important))
                      (NNS:[2368..2377] catalysts))
                    (PP (IN:[2379..2382] for)
                      (NP
                        (NP (DT:[2383..2386] the) (NN:[2387..2397] activation))
                        (PP (IN:[2398..2400] of)
                          (NP (NN:[2401..2416] 6-aminochrysene)))
                        (PP-LOC (IN:[2417..2419] in)
                          (NP
                            (NP (NN:[2420..2425] liver)
                                (NNS:[2426..2436] microsomes))
                            (PP (IN:[2437..2439] of)
                              (NP
                                (ADJP (NN:[2440..2442] PB) (HYPH:[2442..2443] -)
                                      (VBN:[2443..2450] treated))
                                (NNS:[2451..2455] rats)))))))))))))
        (,:[2455..2456] ,) (CC:[2458..2461] and)
        (SBAR (IN:[2462..2466] that)
          (S
            (NP-SBJ
              (NP (NN:[2467..2477] activation))
              (PP (IN:[2478..2480] by)
                (NP
                  (ADJP (NN:[2481..2484] BNF) (HYPH:[2484..2485] -)
                        (VBN:[2485..2492] induced))
                   (NN:[2493..2497] P450) (NNS:[2498..2505] enzymes))))
            (VP (VBZ:[2506..2512] occurs)
              (PP (IN:[2513..2515] by)
                (NP (JJ:[2516..2525] different) (NNS:[2526..2536] mechanisms)))
              (,:[2536..2537] ,)
              (FRAG-ADV
                (ADVP (RB:[2539..2547] probably))
                (PP (IN:[2548..2555] through)
                  (NP (DT:[2556..2559] the) (NN:[2560..2564] ring)
                      (NN:[2565..2574] oxidation) (NN:[2575..2582] pathway)))))))))
    (.:[2582..2583] .)))

;section 13 Span:2587..2631
;PMID: 1530660 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2587..2591] PMID) (::[2591..2592] :) (CD:[2593..2600] 1530660)
        (-LRB-:[2601..2602] -LSB-) (NNP:[2602..2608] PubMed)
        (HYPH:[2609..2610] -) (VBN:[2611..2618] indexed) (IN:[2619..2622] for)
        (NNP:[2623..2630] MEDLINE) (-RRB-:[2630..2631] -RSB-)))
